Date(s) - 19 Jun 2013
10:00 AM - 11:00 AM
Venture Philanthropy Models:
The Leukemia & Lymphoma Society’s Therapy Acceleration Program
Wednesday, June 19, 2013
10:00 – 11:00 AZ /1:00 – 2:00 p.m. ET
The Therapy Acceleration Program (TAP) at The Leukemia & Lymphoma Society (LLS) is a strategic initiative to speed the development of blood cancer treatments and supportive diagnostics. TAP looks to fund projects related to therapies that have the potential to change the standard of care for patients with blood cancer, especially in areas of high unmet medical need. TAP funding assists both clinical investigators and companies in gaining critical proof-of-concept data that better enable them to obtain the resources they need or a partner to complete the testing, registration, and marketing of new treatments for leukemia, lymphoma, multiple myeloma, and other blood cancers.
In this Webinar you will learn about the elements of the program, including:
- the Academic Concierge division, which supports translation of projects in the academic grant portfolio
- the Biotechnology Accelerator division, which invests in companies to assist in gaining proof-of-concept findings and leveraging follow-on funding
- the Clinical Trials division, which plans to introduce a network of Phase I and II clinical trial sites to accelerate studies in blood cancers
- the Targets, Leads and Candidates program, which allows industry to leverage LLS’s infrastructure for the identification and acceleration of innovative research at academic centers in priority research areas with significant unmet medical need
The presenters will be:
- Louis DeGennaro, Ph.D., Chief Mission Officer, Leukemia & Lymphoma Society
- Lawrence Mayer, Ph.D., Founder, President, and Head of Research, Celator Pharmaceuticals, Inc.
Help shape the discussion! Submit questions in advance to the presenters when you register or by sending an email to email@example.com.